Metallothionein and Superoxide DismutaseAntioxidative Protein Status in Fullerene-Doxorubicin Delivery to MCF-7 Human Breast Cancer Cells

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16370%2F18%3A43876758" target="_blank" >RIV/62157124:16370/18:43876758 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.mdpi.com/1422-0067/19/10/3253/htm" target="_blank" >https://www.mdpi.com/1422-0067/19/10/3253/htm</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/ijms19103253" target="_blank" >10.3390/ijms19103253</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Metallothionein and Superoxide DismutaseAntioxidative Protein Status in Fullerene-Doxorubicin Delivery to MCF-7 Human Breast Cancer Cells

Popis výsledku v původním jazyce

Doxorubicin (DOX) is one of the most frequently used anticancer drugs in breast cancer treatment. However, clinical applications of DOX are restricted, largely due to the fact that its action disturbs the pro/antioxidant balance in both cancerous and non-cancerous cells. The aim of this study was to investigate the influence of fullerene (C-60) in cell treatment by DOX on the proliferation of human breast cancer cells (MCF-7), concentration of metallothionein (MT) and superoxide dismutase (SOD), and SOD activity in these cells. The use of C-60 in complexes with DOX causes a change in the level of cell proliferation of about 5% more than when caused by DOX alone (from 60-65% to 70%). The use of C-60 as a DOX nanotransporter reduced the MT level increase induced by DOX. C-60 alone caused an increase of SOD1 concentration. On the other hand, it led to a decrease of SOD activity. C-60 in complex with DOX caused a decrease of the DOX-induced SOD activity level. Exposure of MCF-7 cells to DOX-C-60 complexes results in a decrease in viable cells and may become a new therapeutic approach to breast cancer. The effects of C-60 in complexes with DOX on MCF-7 cells included a decreased enzymatic (SOD activity) and nonenzymatic (MT) antioxidant status, thus indicating their prooxidant role in MCF-7 cells.

Název v anglickém jazyce

Metallothionein and Superoxide DismutaseAntioxidative Protein Status in Fullerene-Doxorubicin Delivery to MCF-7 Human Breast Cancer Cells

Popis výsledku anglicky

Doxorubicin (DOX) is one of the most frequently used anticancer drugs in breast cancer treatment. However, clinical applications of DOX are restricted, largely due to the fact that its action disturbs the pro/antioxidant balance in both cancerous and non-cancerous cells. The aim of this study was to investigate the influence of fullerene (C-60) in cell treatment by DOX on the proliferation of human breast cancer cells (MCF-7), concentration of metallothionein (MT) and superoxide dismutase (SOD), and SOD activity in these cells. The use of C-60 in complexes with DOX causes a change in the level of cell proliferation of about 5% more than when caused by DOX alone (from 60-65% to 70%). The use of C-60 as a DOX nanotransporter reduced the MT level increase induced by DOX. C-60 alone caused an increase of SOD1 concentration. On the other hand, it led to a decrease of SOD activity. C-60 in complex with DOX caused a decrease of the DOX-induced SOD activity level. Exposure of MCF-7 cells to DOX-C-60 complexes results in a decrease in viable cells and may become a new therapeutic approach to breast cancer. The effects of C-60 in complexes with DOX on MCF-7 cells included a decreased enzymatic (SOD activity) and nonenzymatic (MT) antioxidant status, thus indicating their prooxidant role in MCF-7 cells.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Molecular Sciences

ISSN

1422-0067

e-ISSN

—

Svazek periodika

19

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

17

Strana od-do

—

Kód UT WoS článku

000448951000408

EID výsledku v databázi Scopus

—